Rational design of hypoallergens applied to the major cat allergen Fel d 1

Clinical and Experimental Allergy

Volumn 35, Issue 5, 2005, Pages 657-663

  Saarne, T ^a   Kaiser, L ^a,b   Grönlund, Hans ^a,b   Rasool, O ^a,c   Gafvelin, G ^a   Van Hage Hamsten, M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Allergen specific immunotherapy; Allergy; Cat allergen; CD203c; CD63; Fel d 1; Hypoallergen; T cell epitope

Indexed keywords

ALLERGEN; ANTIGEN; CD203C ANTIGEN; CD63 ANTIGEN; EPITOPE; FEL D 1 ALLERGEN; IMMUNOGLOBULIN E; UNCLASSIFIED DRUG;

ALLERGENICITY; ALLERGY; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BASOPHIL; CAT; CONTROLLED STUDY; DISULFIDE BOND; DRUG DESIGN; DRUG EFFICACY; DRUG ISOLATION; DRUG SAFETY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; STRUCTURE ANALYSIS; SYMPTOM; T LYMPHOCYTE; THREE DIMENSIONAL IMAGING;

ALLERGENS; ANIMALS; B-LYMPHOCYTES; BASOPHILS; CATS; CELL DIVISION; EPITOPES; GENETIC ENGINEERING; GLYCOPROTEINS; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOTHERAPY, ACTIVE; POINT MUTATION; RECOMBINANT PROTEINS; RECOMBINATION, GENETIC; T-LYMPHOCYTES;

EID: 20044391870     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2005.02234.x     Document Type: Article

References (42)

1. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102:558-62.
2. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002; 2:446-53.
3. Akdis CA, Blaser K. Regulation of specific immune responses by chemical and structural modifications of allergens. Int Arch Allergy Immunol 2000; 121:261-9.
4. Vrtala S, Hirtenlehner K, Vangelista L et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 1997; 99:1673-81.
5. Vrtala S, Hirtenlehner K, Susani M et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J 2001; 15:2045-7.
6. Norman PS, Ohman JL Jr, Long AA et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996; 154:1623-8.
7. Simons FE, Imada M, Li Y, Watson WT, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1996; 8:1937-45.
8. Oldfield WLG, Larché M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002; 360:47-53.
9. Freidhoff LR, Meyers DA, Marsh DG. A genetic-epidemiologic study of human immune responsiveness to allergens in an industrial population. II. The associations among skin sensitivity, total serum IgE, age, sex, and the reporting of allergies in a stratified random sample. J Allergy Clin Immunol 1984; 73:490-9.
10. Plaschke P, Janson C, Norrman E et al. Skin prick tests and specific IgE in adults from three different areas of Sweden. Allergy 1996; 51:461-72.
11. Roost HP, Künzli N, Schindler C et al. Role of current and childhood exposure to cat and atopic sensitization. European Community Respiratory Health Survey. J Allergy Clin Immunol 1999; 104:941-7.
12. van Ree R, van Leeuwen WA, Bulder I, Bond J, Aalberse RC. Purified natural and recombinant Fel d 1 and cat albumin in in vitro diagnostics for cat allergy. J Allergy Clin Immunol 1999; 104:1223-30.
13. Ichikawa K, Iwasaki E, Baba M, Chapman MD. High prevalence of sensitization to cat allergen among Japanese children with asthma, living without cats. Clin Exp Allergy 1999; 29:754-61.
14. Kristensen AK, Schou C, Roepstorff P. Determination of isoforms, N-linked glycan structure and disulfide bond linkages of the major cat allergen Fel d 1 by a mass spectrometric approach. Biol Chem 1997; 378:899-908.
15. Duffort OA, Carreira J, Nitti G, Polo F, Lombardero M. Studies on the biochemical structure of the major cat allergen Felis domesticus I. Mol Immunol 1991; 28:301-9.
16. Morgenstern JP, Griffith IJ, Brauer AW et al. Amino acid sequence of Fel dI, the major allergen of the domestic cat: protein sequence analysis and cDNA cloning. Proc Natl Acad Sci USA 1991; 88:9690-4.
17. Griffith IJ, Craig S, Pollock J, Yu XB, Morgenstern JP, Rogers BL. Expression and genomic structure of the genes encoding FdI, the major allergen from the domestic cat. Gene 1992; 113:263-8.
18. Bond JF, Brauer AW, Segal DB, Nault AK, Rogers BL, Kuo MC. Native and recombinant Fel dI as probes into the relationship of allergen structure to human IgE immunoreactivity. Mol Immunol 1993; 30:1529-41.
19. Grönlund H, Bergman T, Sandström K et al. Formation of disulfide bonds and homodimers of the major cat allergen Fel d 1 equivalent to the natural allergen by expression in Escherichia coli. J Biol Chem 2003; 278:40144-51.
20. Saarne T, Kaiser L, Rasool O, Huecas S, van Hage-Hamsten M, Gafvelin G. Cloning and characterisation of two IgE-binding proteins, homologous to tropomyosin and alpha-tubulin, from the mite Lepidoglyphus destructor. Int Arch Allergy Immunol 2003; 130:258-65.
21. Counsell CM, Bond JF, Ohman JL Jr, Greenstein JL, Garman RD. Definition of the human T-cell epitopes of Fel d 1, the major allergen of the domestic cat. J Allergy Clin Immunol 1996; 98: 884-94.
22. Kaiser L, Gafvelin G, Johansson E, van Hage-Hamsten M, Rasool O. Lep d 2 polymorphisms in wild and cultured Lepidoglyphus destructor mites. Eur J Biochem 2003; 270:646-53.
23. Hauswirth AW, Natter S, Ghannadan M et al. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol 2002; 110:102-9.
24. Valent P, Hauswirth AW, Natter S, Sperr WR, Bühring HJ, Valenta R. Assays for measuring in vitro basophil activation induced by recombinant allergens. Methods 2004; 32:265-70.
25. Eriksson TLJ, Gafvelin G, Elfman LH, Johansson C, van Hage-Hamsten M, Olsson S. T cell responses to recombinant isoforms, synthetic peptides and a mutant variant of Lep d 2, a major allergen from the dust mite Lepidoglyphus destructor. Clin Exp Allergy 2001; 31:1881-90.
26. Plaschke P, Janson C, Norrman E, Björnsson E, Ellbjär S, Järvholm B. Association between atopic sensitization and asthma and bronchial hyperresponsiveness in Swedish adults: pets, and not mites, are the most important allergens. J Allergy Clin Immunol 1999; 104:58-65.
27. Van Metre TE Jr, Marsh DG, Adkinson NF Jr et al. Immunotherapy for cat asthma. J Allergy Clin Immunol 1988; 82: 1055-68.
28. Hedlin G, Graff-Lonnevig V, Heilborn H et al. Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 1991; 87:955-64.
29. Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Herranz C, Blanco-Quiros A. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol 1994; 93:556-66.
30. Varney VA, Edwards J, Tabbah K, Brewster H, Mavroleon G, Frew AJ. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997; 27:860-7.
31. Akdis CA, Blesken T, Wymann D, Akdis M, Blaser K. Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. Eur J Immunol 1998; 28:914-25.
32. Ball T, Sperr WR, Valent P et al. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 1999; 29:2026-36.
33. Mothes N, Heinzkill M, Drachenberg KJ et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003; 33:1198-208.
34. Kaiser L, Grönlund H, Sandalova T et al. Production, crystallization and preliminary crystallographic study of the major cat allergen Fel d 1. Acta Crystallogr D Biol Crystallogr 2003; 59:1103-5.
35. Kaiser L, Grönlund H, Sandalova T et al. The crystal structure of the major cat allergen Fel d 1, a member of the secretoglobin family. J Biol Chem 2003; 278:37730-5.
36. van Milligen FJ, van't Hof W, van den Berg M, Aalberse RC. IgE epitopes on the cat (Felis domesticus) major allergen Fel d I: a study with overlapping synthetic peptides. J Allergy Clin Immunol 1994; 93:34-43.
37. Mirza O, Henriksen A, Ipsen H et al. Dominant epitopes and allergic cross-reactivity: complex formation between a Fab fragment of a monoclonal murine IgG antibody and the major allergen from birch pollen Bet v 1. J Immunol 2000; 165:331-8.
38. Smith AM, Chapman MD. Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2. Mol Immunol 1996; 33:399-405.
39. Takai T, Yokota T, Yasue M et al. Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy. Nat Biotechnol 1997; 15:754-8.
40. Olsson S, van Hage-Hamsten M, Whitley P. Contribution of disulphide bonds to antigenicity of Lep d 2, the major allergen of the dust mite Lepidoglyphus destructor. Mol Immunol 1998; 35:1017-23.
41. Arquint O, Helbling A, Crameri R, Ferreira F, Breitenbach M, Pichler WJ. Reduced in vivo allergenicity of Bet v Id isoform, a natural component of birch pollen. J Allergy Clin Immunol 1999; 104:1239-43.
42. Hard T, Barnes HJ, Larsson C, Gustafsson JA, Lund J. Solution structure of a mammalian PCB-binding protein in complex with a PCB. Nat Struct Biol 1995; 2:983-9.